Skip to main content
Shaanxi Meibang Pharmaceutical Group Co., Ltd. logo

Shaanxi Meibang Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 605033 ISIN · CNE100005071 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 633 across all filing types
Latest filing 2026-05-22 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 605033

About Shaanxi Meibang Pharmaceutical Group Co., Ltd.

https://www.meibang.cn/

Shaanxi Meibang Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and distribution of crop protection solutions. The company’s portfolio includes a diverse range of fungicides, insecticides, herbicides, and plant growth regulators. Utilizing advanced chemical synthesis and formulation technologies, the group develops products aimed at enhancing crop health and optimizing agricultural yields. The organization operates dedicated research and development centers focused on creating efficient and environmentally conscious formulations. Its activities center on providing integrated pest management and plant nutrition support, offering technical expertise and high-performance products to address various biological challenges in large-scale and specialized farming operations.

Recent filings

Filing Released Lang Actions
陕西美邦药业集团股份有限公司2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an official announcement detailing the outcomes of shareholder votes at the 2025 Annual General Meeting, including vote counts and resolutions passed. This matches the category for Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-22 Chinese
美邦股份2025年年度股东会法律意见书
AGM Information Classification · 60% confidence The document is a legal opinion letter issued by a law firm regarding the convening, legality of procedures, attendee qualifications, voting process and results of the 2025 annual shareholders’ meeting (AGM). It is not the company’s financial report, earnings release, or proxy solicitation statement, nor a standalone audit or lawsuit report. Instead, it serves as meeting material for the AGM, making it best fit the “AGM Information” category (AGM-R) which covers presentations and materials shared at the annual meeting.
2026-05-22 Chinese
陕西美邦药业集团股份有限公司2025年年度股东会会议资料
AGM Information Classification · 94% confidence The document is exclusively the set of materials and agenda for the 2025 Annual General Meeting (股东会会议资料) including meeting notices, agenda items, board work reports, independent director reports, financial reports, and attachments to be presented at the AGM. It is not the annual report itself but materials prepared for the shareholders’ meeting. Therefore, it falls under AGM Information (AGM-R).
2026-05-15 Chinese
陕西美邦药业集团股份有限公司关于参加“2026年陕西辖区上市公司投资者集体接待日暨 2025年度业绩说明会”的公告
Regulatory Filings Classification · 80% confidence The document is a regulatory announcement by the board of Shaanxi Meibang Pharmaceutical Group to participate in a collective investor reception day and host a 2025 performance explanation meeting. It provides meeting date, time, participation method and contact details. It contains no actual financial statements, presentation materials or voting results—only notice of an upcoming investor event. This does not fit specific report or filing types (e.g., 10-K, IR, ER, IP) and is a general regulatory announcement, so it falls into the fallback category RNS.
2026-05-13 Chinese
陕西美邦药业集团股份有限公司关于2025年度募集资金存放、管理与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the storage, management, and actual use of funds raised by the company in 2025. It references regulatory guidelines from the Shanghai Stock Exchange and the China Securities Regulatory Commission, includes detailed financial tables on fundraising amounts, usage, cash management, and project investment, and contains auditor and sponsor verification reports. The document is lengthy (over 9,000 characters) and contains substantive financial data and analysis related to fundraising activities and their compliance. This matches the description of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. It is not an announcement of a report, nor a full annual or interim report, but a specialized report on fundraising usage and management.
2026-04-28 Chinese
陕西美邦药业集团股份有限公司2025年度独立董事述职报告（王楠）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2025 by an independent director of the company. It details the director's background, attendance at board and shareholder meetings, oversight of related party transactions, external guarantees, report disclosures, auditor appointment, and overall evaluation of the director's duties. The content focuses on the independent director's duties and annual work report rather than financial statements or audit results. It is not an annual report (10-K), audit report (AR), or management report (MDA). It is a specific report by an independent director about their annual duties and observations, which fits the category of Board/Management Information (MANG). The document length is under 5,000 characters but contains substantive content, not just an announcement. Therefore, the best classification is MANG with high confidence.
2026-04-28 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.